Zai Lab and Pfizer have entered a strategic collaboration to commercialise XACDURO (sulbactam-durlobactam), a new ...

and his research team have been studying mechanisms of resistance to the beta-lactam antibiotics. In gram-negative bacteria, the most common mechanism of resistance is the hydrolysis, or breaking ...

This new study looked at a combination of three drugs: the β-lactam antibiotic meropenem, a newly developed MBL inhibitor called indole-2-carboxylate 58 (InC58), and an SBL inhibitor called ...

“Beta-lactam antibiotics and beta-lactam resistance inhibitors ... CITATION: “Private Benefit of Β-Lactamase Dictates Selection Dynamics of Combination Antibiotic Treatment,” Helena R.

Conventionally, S. aureus infections were treated with β-lactam antibiotics. Over time, the pathogen developed resistance to the β-lactamase, which led to the introduction of methicillin ...

"Beta-lactam antibiotics and beta-lactam resistance inhibitors ... Ma et al, Private benefit of β-lactamase dictates ...

A welcome advance would be more data on the use of β-lactams, which appear to be well tolerated. Data on aerosolized quinolones may also be available in 5 years, although more likely in other ...

Aerosolized antibiotics are theoretically attractive ... have been a number of reports using aminoglycosides, colistin and β-lactams for treating HAP. However, there has been a sharp increase ...